Campath alemtuzumab: Completed Phase III enrollment

Genzyme completed enrollment of 525 treatment-naïve relapsing-remitting MS patients in the 2-year, single-blind, international Phase III CARE-MS I trial comparing IV alemtuzumab vs. subcutaneous Rebi...